title: Vinorelbine after paclitaxel in breast cancer: cross resistance and cumulative neurotoxicity?
authors.forename: C
authors.initials: C
authors.lastname: Dittrich
authors.forename: U
authors.initials: U
authors.lastname: Zifko
authors.forename: B
authors.initials: B
authors.lastname: Fazeny
authors.forename: M
authors.initials: M
authors.lastname: Fiegl
authors.forename: W
authors.initials: W
authors.lastname: Grisold
authors.forename: H
authors.initials: H
authors.lastname: Huber
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000009:adverse effects*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; D014747:Vinblastine; D017239:Paclitaxel; D000077235:Vinorelbine